AB Vista: From data to decisions - A collaborative approach to gut health interpretation in commercial monogastric animal trials

 

How consistent sampling, structured data analysis, and industry collaboration improve the interpretation of gut health markers.

 

Gut health plays a central role in monogastric animal performance, influencing nutrient utilisation, resilience to disease challenges, and livestock uniformity. To better understand gut function, a range of biomarkers can be measured in commercial trials, including microbial populations, fermentation metabolites such as volatile fatty acids (VFAs), and host response markers such as inflammation indicators.

 

While generating these data has become increasingly accessible, interpreting them remains a challenge. Differences in sampling, biological variability between animals, and the complexity of the gut ecosystem can make it difficult to determine whether observed changes are meaningful or simply part of normal variation.

 

For this reason, selecting relevant and interpretable biomarkers is only the first step. The real challenge lies in translating these measurements into insights that can guide practical decisions in commercial animal production.

 

Addressing this challenge requires more than laboratory measurements alone. It requires a structured and repeatable approach, from sampling design to data analysis and interpretation. At AB Vista, the VistaBiome Gut Health Service was developed to support this full workflow. We work alongside customers to define robust sampling plans, generate high-quality data, and interpret results within their production context. The aim is simple: to turn gut health measurements into insights that can be used with confidence.

 

Consistent sampling and sample preservation

 

Meaningful interpretation begins long before samples reach the laboratory. In commercial production systems, differences in when samples are collected, how they are handled, and how they are stored can introduce variability unrelated to biology. If these factors are not controlled, even high-quality laboratory measurements can become difficult to interpret.

 

Before sampling begins, potential risks and assumptions are considered when designing the sampling plan. Factors such as the number of production units and samples, age, and sampling time points are defined in advance to ensure the study is adequately powered to answer the biological question being investigated.

 

As part of AB Vista's Gut Health Service, we use Biofreeze™, a proprietary sample preservation solution developed by Alimetrics. Biofreeze™ stabilises gut health biomarkers at the point of collection, reducing biomaterial degradation and limiting sample variability during transport and storage.

 

Combined with clear sampling guidelines, this approach improves comparability across farms, commercial trials, and time points, and strengthens the repeatability of results. This ensures that conclusions are not limited to a single sampled environment, but can be applied more broadly across production systems.

 

A structured analytical framework for gut health interpretation

 

Within AB Vista's Gut Health Service, results are interpreted using a structured and repeatable analytical framework that combines biological relevance with statistical rigor. Rather than measuring a large number of biomarkers, this simplification improves interpretability and allows consistent learning across trials and production systems.

 

At the same time, datasets are analysed to understand the variability present across treatments, groups, or sampling points. Unlike traditional performance parameters, gut health biomarkers reflect the status of individuals within a population. Therefore, interpretation does not rely solely on average values but also considers how individual animals respond within a group. This provides additional insight into population behaviour, including variability and uniformity.

 

For example, two groups may show similar average values while one group displays a wider spread of responses. Increased variability within a group can indicate inconsistent responses to the same conditions, which may suggest underlying gut health challenges.

 

To support interpretation, results are also compared against benchmarking datasets generated across multiple farms and commercial trials. These reference ranges help determine whether observed values fall within expected biological variation or represent meaningful deviations that warrant further investigation.

 

Together, this approach helps place gut health measurements within their proper biological and production context to enable informed decision making.

 

Aligning analysis with the biological objective

 

A key principle of AB Vista's Gut Health Service is that analysis should follow the biological objective of the study. When the objective is to compare gut health responses to different diets, additives, or management strategies, the focus is on identifying reliable differences between groups. When the goal is to understand how gut health status changes as dosage, performance, or production conditions vary over time, the focus shifts towards identifying trends and relative changes. The analytical approach is therefore selected not only based on scientific considerations, but also on the practical objectives of the customer.

 

For example, longitudinal analyses may be used to evaluate how biomarkers change over time, distribution comparisons can help identify differences between populations, and regression analyses may be applied to explore relationships between biomarkers. Each method provides a different perspective on how animals respond to a given strategy, allowing interpretation to be tailored to the specific objective of the study.

 

For this reason, clearly defining the objective of the study at the outset is essential – it ensures that the sampling strategy, data structure, and analytical approach are aligned to provide meaningful and interpretable results.

 

Interpreting gut health through collaboration

 

Ultimately, gut health data are only valuable if they help answer questions related to animal performance. In many commercial situations, animal trials are conducted by customers or third-party partners, where key performance parameters such as body weight gain, feed conversion ratio (FCR), and mortality are already collected.

 

AB Vista works collaboratively with customers and partners to interpret gut health results alongside these production datasets. This provides biological context and helps customers understand how changes in gut health status relate to what they observe in the environment.

 

Importantly, this process is conducted as a partnership, respecting the roles and responsibilities of everyone involved in the trial.

 

These collaborations can also generate new biological insights. By analysing gut health responses alongside field observations, we can improve our understanding of product modes of action or correlations between key biomarkers.

 

Studying these dynamic responses also helps identify the most appropriate sampling windows, as some biological differences may only be detectable within specific stages of production.

 

Closing thoughts

 

Transforming gut health data into meaningful performance insights requires more than accurate laboratory measurements. It depends on a well-designed sampling plan and consistent sampling, structured data analysis and interpretation within commercial animal trial settings.

 

AB Vista's Gut Health Service brings these elements together to generate conclusions that customers can trust. By working collaboratively with customers and research partners, we help turn gut health data into decisions that can support better livestock performance.